{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"12"},{"groupId":"OG001","value":"15"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"104"},{"groupId":"OG001","value":"98"}],"units":"Participants"}],"description":"Complete response (CR), evaluated 90 days from transplant, defined as (i) negative immunofixation of the multiple myeloma (MM) protein in urine and serum, (ii) disappearance of any soft tissue plasmacytomas, and (iii) less than 5% plasma MM cells in the bone marrow. International Myeloma Working Group uniform response criteria.","groups":[{"description":"Busulfan with a target daily area under the curve (AUC) of 5000 with Melphalan 70 mg/m2 followed by a stem cell transplant","id":"OG000","title":"Busulfan + Melphalan"},{"description":"High-dose Melphalan 200 mg/m2/day followed by a stem cell transplant","id":"OG001","title":"Melphalan"}],"paramType":"COUNT_OF_PARTICIPANTS","reportingStatus":"POSTED","timeFrame":"Evaluated 90 days from transplant.","title":"Number of Participants With Complete Response (CR)","type":"SECONDARY","unitOfMeasure":"Participants"}